Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID) Clinical Trial

Official title:

Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00782106
• Other study ID #: 160602
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 4, 2006
• Est. completion date: November 1, 2007

Study information

• Verified date: April 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine the feasibility of infusing a full 4-week dose of Immune Globulin Intravenous (Human), 10% in a single subcutaneous site and the amount of recombinant human hyaluronidase needed to infuse that dose with no more than mild local adverse drug reactions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: November 1, 2007
• Est. primary completion date: November 1, 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent from either the subject or the subject's legally acceptable representative

• Diagnosis of a PID disorder as defined by World Health Organization criteria1 for which the subject had been receiving a regimen of weekly or biweekly (every-other-week) subcutaneous IgG infusions or IGIV infusions every 21 to 28 days over a period of at least 8 weeks pre-study at an equivalent of a 4-week dose of 300 to 800 mg/kg bodyweight

• Adults/adolescents aged 16 years and older)

• For female subjects of child-bearing age: negative urine pregnancy test result at study entry and agreement to employ adequate birth control measures for the duration of the study

Exclusion Criteria:

• Subjects positive at enrollment for one or more of the following: HBsAg, PCR for HCV, PCR for HIV Type 1

• Subjects with levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal for the testing laboratory

• Subjects with neutropenia (defined as an absolute neutrophil count [ANC] <= 500/mm3).

• Subjects with serum creatinine levels greater than 1.5 times the upper limit of normal for age and gender

• Subjects with current history of malignancy

• Subjects with a history of thrombotic episodes (deep vein thrombosis, myocardial infarction, cerebrovascular accident)

• Subjects with abnormal protein loss (protein losing enteropathy, nephritic syndrome, severe lung disease)

• Subjects with anemia that in the opinion of the investigator precluded phlebotomy for laboratory studies

• Subjects who had been exposed to any blood or blood product other than an intravenous immunoglobulin (IGIV), SC immunoglobulin (SCIG), immune serum globulin (ISG) preparations, or albumin within the 6 months prior to study entry.

• Subjects with an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV, SCIG and/or ISG infusions

• Subjects with IgA deficiency and known anti IgA antibodies

• Subjects who had received antibiotic therapy for the treatment of infection within 7 days prior to enrollment

• Subjects who had participated in another clinical study involving an investigational product or device within 28 days prior to study entry

• Subjects with inability or unwillingness to meet all the requirements of this study

• If female, pregnancy or lactation at time of study entry

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Primary Immunodeficiency Diseases (PID)

Intervention

Biological:
• Recombinant human hyaluronidase + immune globulin intravenous
Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
• Recombinant human hyaluronidase + immune globulin intravenous
IV infusion of IGIV, 10% to determine pharmacokinetics Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered

Locations

Country	Name	City	State
United States	First Allergy and Clinical Research Center	Centennial	Colorado
United States	Pediatrics Allergy/Immunology Association, PA	Dallas	Texas
United States	Allergy Associates of the Palm Beaches	North Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Baxalta now part of Shire

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability to administer, after priming with recombinant human hyaluronidase, at least one half of a 4-week dose (minimum of 200 mg/kg) of IgG in a single infusion site, via the subcutaneous route, with no more than mild local adverse drug reactions.		72 hours